Volpara’s software enables early detection of breast cancer by utilising its proprietary artificial intelligence (AI) technology to improve breast screening. The technology allows for the objective measurement of breast density, which is associated with breast cancer risk.

Sales are climbing in the huge US market, aided by the acquisition of US based specialist radiology clinic management software provider, MRS Systems in June 2019 for US$14.6m. This has increased the company’s access to number of US breast imaging clinics by five times.

Want to see other interesting ASX Healthcare Shares stocks?